Want to see SE:INIT full AI Analyst Report?
INIT Stock Chart & Stats
kr3.04
-kr0.20(-3.17%)
At close: 4:00 PM EST
kr3.04
-kr0.20(-3.17%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr4.07
Previous CloseN/A
Volume47.38K
Average Volume (3M)133.41K
Market Cap
kr193.72M
Enterprise Valuekr121.90M
Total Cash (Recent Filing)kr19.90M
Total Debt (Recent Filing)kr7.56M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio-7.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Small-molecule PipelineA concentrated, clinical-stage small-molecule pipeline in sexual and reproductive health provides durable strategic clarity and a clear value-creation path via clinical milestones and partnering. This focus supports expertise, targeted R&D spend, and makes later-stage out-licensing or partnerships more feasible over months.
Low Financial LeverageVery low debt reduces fixed financing costs and interest exposure, preserving flexibility to fund development via equity or partnerships. Modest leverage is a durable structural strength enabling management to prioritize trial progress over debt servicing in the next several months.
Improving Free Cash Flow TrendAn improvement in free cash flow versus the prior year indicates the company is moderating cash burn or deriving better cash conversion from operations. While still negative, a sustained FCF improvement reduces immediate funding pressure and lengthens runway, aiding medium-term execution and partner negotiations.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-revenue with materially widening losses, reflecting heavy R&D and operating spending without commercial offset. This structural loss profile forces reliance on external capital and creates execution risk: clinical progress must translate to funding events or partnerships to sustain operations.
Declining Equity BaseA falling equity base signals capital erosion from sustained losses and increases likelihood of dilution from future financings. Over the coming months this reduces the balance-sheet cushion against setbacks and constrains strategic optionality for costly clinical programs without new capital or partner deals.
Persistent Negative Operating Cash FlowOngoing negative operating cash flow is a durable constraint that necessitates repeated external funding or licensing. Even with low debt, consistent cash burn limits the company's ability to scale trials or add capabilities and elevates execution risk until sustainable cash generation or partnership funding is secured.
INIT FAQ
What was Initiator Pharma A/S’s price range in the past 12 months?
Initiator Pharma A/S lowest stock price was kr2.53 and its highest was kr4.07 in the past 12 months.
What is Initiator Pharma A/S’s market cap?
Initiator Pharma A/S’s market cap is kr193.72M.
When is Initiator Pharma A/S’s upcoming earnings report date?
Initiator Pharma A/S’s upcoming earnings report date is Aug 21, 2026 which is in 48 days.
How were Initiator Pharma A/S’s earnings last quarter?
Initiator Pharma A/S released its earnings results on May 08, 2026. The company reported -kr0.242 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.242.
Is Initiator Pharma A/S overvalued?
According to Wall Street analysts Initiator Pharma A/S’s price is currently Overvalued.
Does Initiator Pharma A/S pay dividends?
Initiator Pharma A/S does not currently pay dividends.
What is Initiator Pharma A/S’s EPS estimate?
Initiator Pharma A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Initiator Pharma A/S have?
Initiator Pharma A/S has 68,452,890 shares outstanding.
What happened to Initiator Pharma A/S’s price movement after its last earnings report?
Initiator Pharma A/S reported an EPS of -kr0.242 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.297%.
Which hedge fund is a major shareholder of Initiator Pharma A/S?
Currently, no hedge funds are holding shares in SE:INIT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Initiator Pharma A/S
Initiator Pharma A/S is a clinical-stage life sciences firm dedicated to discovering therapeutic solutions for critical unmet medical needs affecting the central and peripheral nervous systems. Its development pipeline features several clinical-phase compounds: IP2018, a monoamine reuptake inhibitor aimed at psychogenic erectile dysfunction; IPED2015, designed to address organic erectile dysfunction; and IPTN2021, an orphan drug candidate for severe neuropathic pain. Additionally, the company holds early-stage assets, including IPNP2015 for chronic pain management and IPDP2015 for depression. Established in 2016, Initiator Pharma A/S maintains its headquarters in Copenhagen, Denmark.